Triazolam

Comment

J M Jonas. BMJ. 1993.

. 1993 Jul 31;307(6899):328.

doi: 10.1136/bmj.307.6899.328-b.

No abstract available

Comment in

Triazolam. Narrow safety margin is unacceptable.
Vela-Bueno A. Vela-Bueno A. BMJ. 1993 Sep 4;307(6904):626. doi: 10.1136/bmj.307.6904.626. BMJ. 1993. PMID: 8401033 Free PMC article. No abstract available.
Triazolam. Small studies miss the difference.
Adam K, Oswald I. Adam K, et al. BMJ. 1993 Sep 4;307(6904):626. doi: 10.1136/bmj.307.6904.626-a. BMJ. 1993. PMID: 8401034 Free PMC article. No abstract available.
Triazolam. The evidence against is extensive and consistent.
Kales A, Bixler EO, Vgontzas AN. Kales A, et al. BMJ. 1993 Sep 4;307(6904):626. doi: 10.1136/bmj.307.6904.626-b. BMJ. 1993. PMID: 8401035 Free PMC article. No abstract available.

Triazolam. Unpublished manufacturers research unfavourable.
Adam K, Oswald I. Adam K, et al. BMJ. 1993 May 29;306(6890):1475-6. doi: 10.1136/bmj.306.6890.1475-b. BMJ. 1993. PMID: 8292128 Free PMC article. No abstract available.
Triazolam. Weight of evidence supports increased risk.
Kales A, Bixler EO, Vgontzas AN. Kales A, et al. BMJ. 1993 May 29;306(6890):1475. doi: 10.1136/bmj.306.6890.1475-a. BMJ. 1993. PMID: 8357399 Free PMC article. No abstract available.